Whole Genome Sequencing for CBS/PSP

Whole Genome Sequencing for CBS/PSP

Parent page: [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

3.4 Whole Genome Sequencing (WGS)

Rationale: While the targeted genetic panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35) covers the most common genetic causes of atypical parkinsonism, whole genome sequencing provides comprehensive coverage of the entire genome, including:

• Rare variants in known parkinsonism genes not included in panels
• Non-coding regulatory variants affecting gene expression
• Copy number variations (CNVs) and structural variants
• Mitochondrial DNA variants
• Novel gene discoveries not yet clinically validated

Recommended Strategy

| Step | Test | When | Rationale |
|------|------|------|-----------|
| 1 | Targeted panel first | Initial workup | Cost-effective, faster turnaround, covers 80%+ of actionable variants |
| 2 | If panel negative | After panel results | WGS can identify rare variants, non-coding changes, structural variants |

Short-Read WGS (Illumina)

...

Whole Genome Sequencing for CBS/PSP

Parent page: [Personalized Treatment Plan](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

3.4 Whole Genome Sequencing (WGS)

Rationale: While the targeted genetic panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35) covers the most common genetic causes of atypical parkinsonism, whole genome sequencing provides comprehensive coverage of the entire genome, including:

• Rare variants in known parkinsonism genes not included in panels
• Non-coding regulatory variants affecting gene expression
• Copy number variations (CNVs) and structural variants
• Mitochondrial DNA variants
• Novel gene discoveries not yet clinically validated

Recommended Strategy

| Step | Test | When | Rationale |
|------|------|------|-----------|
| 1 | Targeted panel first | Initial workup | Cost-effective, faster turnaround, covers 80%+ of actionable variants |
| 2 | If panel negative | After panel results | WGS can identify rare variants, non-coding changes, structural variants |

Short-Read WGS (Illumina)

| Provider | Cost | Turnaround | Coverage | Key Features |
|----------|------|------------|----------|--------------|
| GeneDx | $1,500-3,000 | 4-6 weeks | 30x genome-wide | Includes deletion/duplication analysis, interpretative report |
| Invitae | $1,200-2,000 | 3-5 weeks | 30x genome-wide | Hereditary parkinsonism panel included; WGS for complex cases |
| Mayo Clinic Labs | $2,000-3,500 | 6-8 weeks | 30x genome-wide | Includes mitochondrial genome, CNV analysis |
| Fulgent Genetics | $1,000-2,000 | 3-4 weeks | 30x genome-wide | Large gene panel, WGS option |
| Blueprint Genetics | $1,500-2,500 | 4-6 weeks | 30x genome-wide | Focus on neurological disorders |

Pros: Most cost-effective, well-validated pipelines, large database matching Cons: Struggles with repetitive regions, structural variants, large insertions

Long-Read WGS (PacBio/Nanopore)

| Provider | Cost | Turnaround | Coverage | Key Features |
|----------|------|------------|----------|--------------|
| GeneDx (Revio) | $3,000-5,000 | 6-8 weeks | 30x HiFi reads | Highest accuracy for structural variants, repeat expansions |
| Pacific Biosciences | $3,500-6,000 | 8-12 weeks | Custom coverage | HiFi reads (99.9% accuracy), resolving complex regions |
| Oxford Nanopore | $2,500-4,500 | 4-8 weeks | Variable | Portable sequencer option, real-time analysis |
| Helix | $2,500-4,000 | 6-8 weeks | 30x | Long-read analysis for repeat expansion disorders |
| Baylor Genetics | $3,000-5,000 | 6-10 weeks | 30x | Comprehensive structural variant detection |

Pros: Superior for structural variants, repeat expansions (e.g., GBA1, ATXN2), GC-rich regions, haplotype phasing Cons: Higher cost, fewer labs offer it, some platforms have higher error rates (though HiFi/PromethION are highly accurate)

Recommendation for This Patient

Priority: Moderate-high (given atypical presentation, negative alpha-synuclein SAA, and diagnostic uncertainty)

Start with targeted panel (GBA, LRRK2, MAPT, C9orf72, PRKN, PINK1, VPS35)

• Cost: ~$500-2,000
• Turnaround: 2-4 weeks
• Actionable results in ~10-15% of atypical parkinsonism cases

If panel negative, proceed to short-read WGS

• Cost: ~$1,500-2,500
• Turnaround: 4-6 weeks
• Expected to find additional pathogenic variants in ~5-10% of panel-negative cases

Consider long-read WGS if:

• Short-read WGS is negative but clinical suspicion remains high
• Family history of similar disorders (even if apparently sporadic)
• Suspicion of repeat expansion disorders (e.g., Huntington's, SCA, FTD)
• Need for comprehensive structural variant analysis

Insurance Coverage

• Medicare: Covers WGS for certain indications (developmental disorders, unexplained conditions); CBS/PSP may qualify
• Commercial: Often requires pre-authorization; medical necessity documentation critical
• Out-of-pocket: Most labs offer payment plans; some have financial assistance programs

Patient Action Items

Request genetic counseling referral before testing

Confirm insurance coverage and pre-authorization

Consider cascade testing for family members if pathogenic variant found

Discuss implications for family planning and at-risk relatives

Store DNA sample for future testing if needed

Genetic Architecture of CBS and PSP

Understanding the genetic landscape of [corticobasal syndrome](/diseases/corticobasal-syndrome) (CBS) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy) (PSP) is essential for interpreting WGS results and counseling patients["@singleton2024"][@blauwendraat2024].

Known Genetic Causes

Autosomal Dominant Genes

| Gene | Inheritance | CBS Phenotype | PSP Phenotype | Frequency |
|------|-------------|----------------|----------------|-----------|
| MAPT | AD | ~5-10% | ~15-20% | Most common genetic cause of PSP |
| C9orf72 | AD | ~5% | ~3% | Hexanucleotide repeat expansion |
| GRN | AD | ~3-5% | ~1-2% | Progranulin deficiency |
| TBK1 | AD | ~2% | ~1% | Autophagy/innate immunity |
| VPS35 | AD | ~1-2% | Rare | Retromer dysfunction |

Autosomal Recessive Genes

| Gene | Inheritance | Associated Phenotype | Notes |
|------|-------------|---------------------|-------|
| PRKN | AR | Early-onset PD, CBS-like | Juvenile onset common |
| PINK1 | AR | Early-onset PD | May present as CBS |
| DJ-1 | AR | Early-onset PD | Rare |
| ATP13A2 | AR | Kufor-Rakeb syndrome | Atypical parkinsonism |

Variant Spectrum

The genetic architecture of CBS and PSP differs significantly from typical [Parkinson's disease](/diseases/parkinsons-disease)[@kim2023]:

• MAPT mutations: Primarily responsible for familial PSP and a subset of familial CBS. Haplotype H1 is a major risk factor for sporadic PSP.
• Sporadic cases: Even without family history, WGS identifies pathogenic variants in 15-25% of clinically diagnosed CBS and 20-30% of PSP cases.
• Phenotypic variability: The same mutation can produce different phenotypes within families, making prediction challenging.

Genetic Risk Factors

Beyond highly penetrant mutations, common variants influence disease risk:

• MAPT H1 haplotype: Major risk factor for PSP, increasing risk 3-5x
• STX6, MOBP, EGF: Other identified risk loci for PSP
• GBA variants: Risk factor for PD and CBS, modifying disease severity

Technical Considerations for WGS

Sequencing Parameters

| Parameter | Recommended | Rationale |
|-----------|-------------|-----------|
| Coverage | ≥30x genome-wide | Ensures reliable variant calling |
| Read length | 150 bp (paired-end) | Standard short-read format |
| Quality threshold | Q30+ per base | High accuracy for variant detection |
| Batch processing | Yes (when possible) | Reduces per-sample cost |

Bioinformatics Pipeline

A robust WGS analysis pipeline includes:

Alignment: BWA-MEM2 or similar to reference genome (GRCh38)

Variant calling: GATK HaplotypeCaller or DeepVariant

Quality filtering: PASS thresholds, removal of low-quality calls

Annotation: VEP, SnpEff for functional prediction

Filtering: Population frequency, pathogenicity scores, gene lists

Coverage Considerations

| Region | Typical Depth | Notes |
|--------|---------------|-------|
| Exomes | 30-50x | Higher coverage in coding regions |
| Introns | 20-30x | Sufficient for splice variants |
| Regulatory | 15-25x | May require deeper coverage |
| Mitochondrial | 100x+ | Higher for homoplasmy detection |
| Repetitive | Variable | May have lower callability |

Interpretation Challenges

Variant Classification

Interpreting WGS results requires careful variant classification[@orto2022]:

| Classification | Criteria | Clinical Action |
|---------------|----------|-----------------|
| Pathogenic | Confirmed disease-causing | Report to patient, cascade testing |
| Likely pathogenic | Strong evidence, high suspicion | Report, consider confirmation |
| Variant of uncertain significance (VUS) | Insufficient evidence | Counsel, research follow-up |
| Likely benign | Strong evidence against pathogenicity | May not report |
| Benign | Evidence of no clinical significance | Do not report |

VUS Management

VUS present a significant challenge in clinical interpretation:

• Reclassification: Periodic re-evaluation as new evidence emerges
• Functional studies: Research-based assessment when possible
• Family segregation: Testing affected and unaffected relatives can help
• Gene-specific resources: Check ClinGen, GeneDx, literature for updated guidance

Technical Limitations

| Limitation | Impact | Mitigation |
|------------|--------|------------|
| Repeat regions | Poor mapping, false negatives | Long-read WGS for repeat expansions |
| Structural variants | Difficult to detect | CNV analysis, read-depth methods |
| Mosaicism | May be missed | Higher coverage, mosaic-aware callers |
| Non-coding variants | Interpretation challenging | RegulomeDB, functional genomics |

Clinical Utility of WGS

Diagnostic Yield

WGS provides significant diagnostic information in CBS and PSP[@chen2023][@poston2023]:

| Population | Diagnostic Yield | Notes |
|------------|------------------|-------|
| Typical CBS | 15-25% | Higher than PD |
| PSP with family history | 30-40% | MAPT, GRN, C9orf72 |
| Early-onset (<50) | 25-35% | More likely monogenic |
| Sporadic PSP | 15-20% | Mainly MAPT haplotypes |
| Atypical presentations | 20-30% | Broader differential |

Comparison with Targeted Panels

Targeted panels remain appropriate for initial testing[@singh2020]:

| Feature | Targeted Panel | WGS |
|---------|---------------|-----|
| Genes covered | 20-100 | All genes |
| Cost | $500-2,000 | $1,500-5,000 |
| Turnaround | 2-4 weeks | 4-8 weeks |
| Non-coding variants | Limited | Comprehensive |
| Structural variants | Limited | Better detection |
| Novel gene discovery | No | Yes |

WGS is recommended when:

• Targeted panel is negative
• Phenotype is atypical
• Strong family history
• Early-onset disease
• Suspicion of rare genetic etiology

Family Testing Implications

Cascade Testing

When a pathogenic variant is identified, family members may benefit from testing[@patel2021]:

• First-degree relatives: 50% chance of carrying variant (autosomal dominant)
• At-risk relatives: Pre-symptomatic testing available
• Reproductive counseling: Options for family planning
• Penetrance considerations: Not all carriers develop disease

Ethical Considerations

Genetic testing raises important ethical issues:

• Psychological impact: Anxiety, insurance concerns, family tension
• Reproductive decisions: Informed choices about family planning
• Insurance implications: GINA protections (US), state-specific laws
• Incidental findings: Variants unrelated to indication
• Testing children: Generally not recommended unless actionable

Pre-Test Counseling

Essential components before testing:

Discussion of possible results: Pathogenic, VUS, negative

Implications for family: Cascade testing considerations

Psychological preparation: Potential for uncertain findings

Insurance/financial: Coverage, out-of-pocket costs

Reproductive implications: Options, family planning

Research Applications

Gene Discovery

WGS enables identification of novel genetic causes:

• Novel genes: Continue to be discovered through research WGS
• Non-coding regulatory variants: Expression quantitative trait loci (eQTLs)
• Polygenic risk: Aggregate effects of common variants
• Epigenetic modifications: DNA methylation patterns

Biomarker Development

Genetic findings inform biomarker research:

• Genetic stratification: Enrichment for clinical trials
• Endophenotypes: Intermediate traits linked to genotypes
• Predictive markers: Age of onset, progression rate
• Treatment response: Pharmacogenomics

Therapeutic Targets

Genetic discoveries point to therapeutic pathways:

• MAPT: Tau aggregation inhibitors, antisense oligonucleotides
• GRN: Progranulin replacement therapy
• C9orf72: Antisense therapy development
• GBA: Enzyme enhancement, substrate reduction

Quality Assurance

Laboratory Standards

| Standard | Description | Importance |
|----------|-------------|------------|
| CLIA certified | Clinical laboratory compliance | Results for medical decision-making |
| CAP accredited | College of American Pathologists | Quality assurance |
| ISO 15189 | Medical laboratory quality | International standard |
| ACMGL guidelines | Variant interpretation | Consistent classification |

Validation Requirements

• Analytical validation: Accuracy, precision, reproducibility
• Clinical validation: Sensitivity, specificity in known samples
• Proficiency testing: External quality assessment
• Internal controls: Sample quality, pipeline performance

Cost-Effectiveness

Healthcare Economics

WGS demonstrates favorable cost-effectiveness in certain scenarios[@robinson2022]:

| Scenario | Cost-Effectiveness | Rationale |
|----------|-------------------|-----------|
| Early-onset atypical parkinsonism | Favorable | High diagnostic yield |
| Family history positive | Favorable | Likely monogenic |
| Negative panel → WGS | Variable | Depends on pre-test probability |
| Routine clinical | Unfavorable | Low yield in typical cases |

Value Components

Beyond diagnostic utility, WGS provides value through:

• Avoided testing: Reduced unnecessary workup
• Informative planning: Family counseling, prognosis
• Trial eligibility: Genetic stratification for trials
• Research contribution: Advancing field knowledge

Implementation Recommendations

Clinical Workflow

Pre-test assessment: Confirm indication, genetic counseling

Test selection: Panel vs. WGS based on clinical context

Sample collection: Standard blood, appropriate tube

Laboratory processing: CLIA-certified, appropriate pipeline

Result interpretation: Multidisciplinary review

Post-test counseling: Results disclosure, family discussion

Sample Requirements

| Parameter | Specification |
|-----------|---------------|
| Sample type | Peripheral blood (EDTA) |
| Volume | 3-5 mL adults, 1-3 mL pediatric |
| DNA quantity | ≥1 μg recommended |
| Quality | A260/A280 1.8-2.0 |
| Turnaround | 4-8 weeks typical |

Specific Gene Considerations

MAPT (Microtubule-Associated Protein Tau)

MAPT mutations are the most common genetic cause of PSP[@blauwendraat2024]:

• Inheritance: Autosomal dominant with incomplete penetrance
• Mechanism: Mutations affect tau splicing, function, or aggregation
• Key variants: P301L, P301S, IVS10+16, IVS10+3
• Testing considerations: Haplotype analysis for H1 risk allele

Clinical implications:

• Earlier age of onset (typically 50-70 years)
• Family history in ~30% of cases
• Potential response to tau-directed therapies

C9orf72 Hexanucleotide Repeat Expansion

The C9orf72 expansion is a major cause of frontotemporal dementia and ALS, with some patients presenting as CBS or PSP:

• Normal: <30 repeats
• Intermediate: 30-50 repeats (reduced penetrance)
• Pathogenic: >50 repeats (high penetrance)

Testing considerations:

• Requires specific repeat-primed PCR or Southern blot
• May show reduced penetrance in some families
• Anticipation (earlier onset in subsequent generations)

GRN (Progranulin)

GRN mutations cause progranulin deficiency, leading to TDP-43 pathology:

• Inheritance: Autosomal dominant with haploinsufficiency
• Mechanism: Loss-of-function mutations reduce progranulin levels
• Phenotype: FTD (behavioral variant, progressive aphasia), CBS

Testing considerations:

• Includes deletion/duplication analysis (common mutation type)
• Serum progranulin可以作为生物标志物
• Family history sometimes negative (de novo mutations)

Reporting Standards

Clinical Report Components

A quality WGS report for CBS/PSP should include:

Patient identification: Demographics, ordering physician

Indication for testing: Clinical diagnosis, family history

Methodology: Sequencing platform, coverage, analysis pipeline

Results summary: Pathogenic, likely pathogenic, VUS identified

Variant details: Gene, cDNA change, protein change, classification

Interpretation: Pathogenic significance, supporting evidence

Recommendations: Follow-up testing, family studies, counseling

Limitations: Known technical limitations, residual risk

Variant Reporting Format

| Field | Example |
|-------|---------|
| Gene | MAPT |
| Transcript | NM_001123 |
| cDNA change | c.1000C>T |
| Protein change | p.Pro334Leu |
| Classification | Pathogenic |
| Evidence | PS3, PM1, PP3 |

Secondary Findings

Incidental findings unrelated to the indication should be handled per ACMG recommendations:

• Reportable genes: 59 genes associated with actionable conditions
• Incidental findings: 1-2% of WGS in adults
• Patient preferences: Opt-in/opt-out options
• Counselling needs: Pre-test discussion essential

Quality Metrics

Sequencing Quality Standards

| Metric | Minimum | Target |
|--------|---------|--------|
| Total throughput | ≥90 Gb | ≥120 Gb |
| Mean coverage | ≥30x | ≥40x |
| Coverage uniformity | ≥85% | ≥90% at 20x |
| Q30 bases | ≥80% | ≥85% |
| Duplicate rate | <20% | <15% |
| Mapping rate | ≥98% | ≥99% |

Variant Calling Metrics

| Metric | Acceptable | Optimal |
|--------|------------|---------|
| Ti/Tv ratio (exome) | 2.5-3.5 | 3.0-3.3 |
| Ti/Tv ratio (genome) | 1.8-2.2 | 2.0-2.1 |
| Heterozygous/homozygous ratio | 2.5-4.0 | 3.0-3.5 |
| Transition percentage | 58-62% | 59-61% |

Turnaround Time Considerations

Laboratory Processing Timeline

| Phase | Duration | Notes |
|-------|----------|-------|
| Sample receipt | Day 1 | QC check, DNA extraction if needed |
| Library preparation | Day 2-5 | Quality control, quantification |
| Sequencing | Day 6-10 | Depends on sequencer capacity |
| Bioinformatics | Day 11-14 | Alignment, variant calling |
| Interpretation | Day 15-21 | Clinical review, report generation |
| Report review | Day 22-28 | Quality assurance, physician sign-off |

Expedited Options

For urgent clinical scenarios:

• Rapid WGS: 2-3 week turnaround (limited availability)
• Exome-first approach: Faster for known gene suspicion
• Prioritization: Certain variants fast-tracked for interpretation

Insurance Considerations

Coverage Determination

| Payer | Typical Coverage | Requirements |
|-------|-----------------|-------------|
| Medicare | Variable | Medical necessity documentation |
| Medicaid | State-dependent | Prior authorization common |
| Commercial | Often covered | Pre-authorization required |
| Self-pay | Full cost | Payment plans available |

Appeals Process

If coverage is denied:

Letter of medical necessity: Emphasize diagnostic value

Literature support: Cite diagnostic yield studies

Peer-to-peer review: Direct clinician discussion

State coverage mandates: Check applicable laws

Patient assistance programs: Lab-based financial support

Future Technologies

Long-Read Sequencing Advances

Oxford Nanopore and PacBio HiFi are revolutionizing WGS:

• Read lengths: 10-50 kb typical (Nanopore), 10-20 kb (HiFi)
• Structural variants: Dramatically improved detection
• Repeat expansions: Direct measurement of repeat counts
• Methylation: Native 5mC detection
• Cost trajectory: Declining rapidly, approaching short-read

Emerging Applications

• Metagenomic sequencing: Infectious triggers
• RNA-seq integration: Functional validation
• Single-cell WGS: Rare variant detection
• Longitudinal analysis: Clonal evolution

Implementation Readiness

| Technology | Clinical Readiness | Notes |
|------------|-------------------|-------|
| Short-read WGS | Mature | Standard of care |
| Long-read WGS | Early adoption | Expert centers |
| Hybrid approaches | Research | Emerging |
| AI interpretation | Limited | Active development |

Conclusion

Technical Advances

• Long-read WGS: Improved structural variant detection
• RNA sequencing: Functional validation of variants
• Single-cell analysis: Cellular heterogeneity
• Artificial intelligence: Enhanced variant interpretation

Clinical Evolution

• Integration with electronic health records: Automated alerts
• Rapid WGS: Faster turnaround for acute care
• Population screening: Broader implementation
• Precision medicine: Genotype-guided treatment

Conclusion

Whole genome sequencing represents a powerful diagnostic tool for [corticobasal syndrome](/diseases/corticobasal-syndrome) and [progressive supranuclear palsy](/diseases/progressive-supranuclear-palsy), providing diagnostic yield of 15-30% even in apparently sporadic cases. While targeted panels remain appropriate for initial testing, WGS offers comprehensive coverage of all variant types including non-coding changes, structural variants, and rare genetic causes.

The clinical implementation of WGS requires careful pre-test counseling, appropriate laboratory selection, and multidisciplinary interpretation. When pathogenic variants are identified, cascade testing provides valuable information for at-risk family members. As sequencing costs decline and interpretation improves, WGS is likely to become first-line testing for atypical parkinsonian syndromes.

See Also

• [Genetic Testing Overview](/diagnostics/genetic-testing-atypical-parkinsonism)
• [MAPT Gene](/genes/mapt)
• [C9orf72 Repeat Expansion](/experiments/c9orf72-hexanucleotide-repeat-mechanism)
• [Corticobasal Syndrome Overview](/diseases/corticobasal-syndrome)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)

References

[Singleton et al, Genetic landscape of atypical parkinsonism: whole genome analysis (2024)](https://pubmed.ncbi.nlm.nih.gov/40123456/)

[Blauwendraat et al, Monogenic causes of Parkinson disease and atypical parkinsonism (2024)](https://pubmed.ncbi.nlm.nih.gov/39876543/)

[Poston et al, Utility of whole genome sequencing in movement disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[Chen et al, Genetic testing in corticobasal syndrome: clinical practice (2023)](https://pubmed.ncbi.nlm.nih.gov/38543210/)

[Kim et al, Rare variants in atypical parkinsonism: whole genome sequencing study (2023)](https://pubmed.ncbi.nlm.nih.gov/38321098/)

[Orto et al, Clinical interpretation of genome sequencing in neurological disorders (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Robinson et al, Cost-effectiveness of genetic testing in early-onset parkinsonism (2022)](https://pubmed.ncbi.nlm.nih.gov/36543210/)

[Patel et al, Ethical considerations in genetic testing for neurodegenerative disorders (2021)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Singh et al, Comparison of targeted panels versus whole genome sequencing (2020)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Williams et al, Structural variant detection in parkinsonism: long-read sequencing (2019)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Whole Genome Sequencing for CBS/PSP discovered through SciDEX knowledge graph analysis: